Everolimus (RAD001): an mTOR inhibitor for the treatment of metastatic renal cell carcinoma

Phase II study of bevacizumab and everolimus (RAD001) in the treatment of advanced renal cell carcinoma (RCC)

(2017) R. C. Whorf et al.   JOURNAL OF CLINICAL ONCOLOGY

Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC)

(2017) R. A. Figlin et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase II Trial of First-Line Treatment With Sorafenib Versus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma

(2009) Bernard Escudier et al.   JOURNAL OF CLINICAL ONCOLOGY

Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features

(2008) J. Bellmunt et al.   ANNALS OF ONCOLOGY

The changing pattern of kidney cancer incidence and mortality in Europe

(2008) Fabio Levi et al.   BJU INTERNATIONAL

Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma

(2008) Robert J. Motzer et al.   CANCER

Antiangiogenic Therapy with Mammalian Target of Rapamycin Inhibitor RAD001 (Everolimus) Increases Radiosensitivity in Solid Cancer

(2008) P. C. Manegold et al.   CLINICAL CANCER RESEARCH

Update on the Medical Treatment of Metastatic Renal Cell Carcinoma

(2008) Alain Ravaud et al.   EUROPEAN UROLOGY

Everolimus: an update on the mechanism of action, pharmacokinetics and recent clinical trials

(2008) Ana I Sánchez-Fructuoso   Expert Opinion on Drug Metabolism & Toxicology

Experimental therapy for advanced renal cell carcinoma

(2008) Thomas E Hutson et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Sunitinib (SUTENT®) for the treatment of metastatic renal cell carcinoma

(2008) Thomas E Hutson   Expert Review of Anticancer Therapy

Identifying Optimal Biologic Doses of Everolimus (RAD001) in Patients With Cancer Based on the Modeling of Preclinical and Clinical Pharmacokinetic and Pharmacodynamic Data

(2008) Chiaki Tanaka et al.   JOURNAL OF CLINICAL ONCOLOGY

Lapatinib Versus Hormone Therapy in Patients With Advanced Renal Cell Carcinoma: A Randomized Phase III Clinical Trial

(2008) Alain Ravaud et al.   JOURNAL OF CLINICAL ONCOLOGY

Outcome After Surgical Resections of Recurrent Chest Wall Sarcomas

(2008) Michael W. Wouters et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy of RAD001 (Everolimus) and Octreotide LAR in Advanced Low- to Intermediate-Grade Neuroendocrine Tumors: Results of a Phase II Study

(2008) James C. Yao et al.   JOURNAL OF CLINICAL ONCOLOGY

Dose- and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus: A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors

(2008) Josep Tabernero et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With Advanced Solid Tumors

(2008) Anne O'Donnell et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206

(2008) Brian I. Rini et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

(2008) Robert J Motzer et al.   LANCET

Targeted Therapies for Metastatic Renal Cell Carcinoma: An Overview of Toxicity and Dosing Strategies

(2008) T. E. Hutson et al.   ONCOLOGIST

Toxicities Associated with the Administration of Sorafenib, Sunitinib, and Temsirolimus and Their Management in Patients with Metastatic Renal Cell Carcinoma

(2007) Naeem Bhojani et al.   EUROPEAN UROLOGY